MRTX - Mirati stock up 9% amid FDA meeting on rival Amgen drug
2023-10-05 12:48:51 ET
More on Mirati Therapeutics
- Mirati: Expansion Of Adagrasib With sNDA And Combination Studies
- Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript
- Jones Research sees Amgen FDA issues reading through to Mirati
- Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug
For further details see:
Mirati stock up 9% amid FDA meeting on rival Amgen drug